Back to results
US 2014/0193920 A1Published application
Metabolomics of human biological fluids identify signatures of malignant glioma
OwnerEric T. Wong, John M. Asarainventors
Life of this patent
Estimating the term…
Abstract
A method of identifying a patient in need of therapy to treat a malignant glioma comprising measuring a panel of polar metabolite levels in a biological sample taken from the patient and implementing a therapy to treat the malignant glioma in the patient.
Claims22
A method of identifying a patient in need of therapy to treat a malignant glioma comprising
- (a) measuring a panel of polar metabolite levels in a biological sample taken from the patient, wherein the polar metabolites are measured using a liquid chromatography/tandem mass spectrometry based platform;
- (b) determining the levels of two or more polar metabolites present in the patient sample, wherein the polar metabolites comprise the polar metabolites in Supplemental Table S1;
- (c) comparing the levels of the polar metabolites present in the sample to control levels, wherein a difference in the levels of two or more polar metabolites present in the sample relative to the control levels is indicative of the patient having a malignant glioma;
- and
- (d) implementing a therapy to treat the malignant glioma in the patient.
2 more elements
A method of identifying a patient in need of therapy to treat a recurrent malignant glioma comprising
- (a) measuring a panel of polar metabolite levels in a biological sample taken from the patient, wherein the polar metabolites are measured using a liquid chromatography/tandem mass spectrometry based platform;
- (b) determining the levels of two or more polar metabolites present in the patient sample, wherein the polar metabolites comprise the polar metabolites in Supplemental Table S1,
- (c) comparing the levels of the polar metabolites present in the sample to control levels, wherein a difference in the levels of the two or more polar metabolites present in the sample relative to the control levels is indicative of the patient having a recurrent malignant glioma;
- and
- (d) implementing a therapy to treat the recurrent malignant glioma in the patient.
2 more elements
A method of monitoring a patient's response to treatment of a malignant glioma comprising
- (a) measuring a panel of polar metabolite levels in a biological sample taken from the patient, wherein the polar metabolites are measured using a liquid chromatography/tandem mass spectrometry based platform;
- (b) determining the levels of two or more polar metabolites present in the patient sample, wherein the polar metabolites comprise the polar metabolites in Supplemental Table S1;
- (c) comparing the levels of the metabolites present in the sample to control levels, wherein a difference in the levels of the two ore more polar metabolites present in the sample relative to the control levels is indicative of the patient not responding to the treatment of the malignant glioma;
- and
- (d) implementing a therapy to treat the malignant glioma in the patient.
2 more elements
Dependencies are inferred from the claim text.